Allergy Immunotherapy Market Report Scope & Overview:

The Allergy Immunotherapy Market was valued at USD 2.1 billion in 2025 and is expected to reach USD 5.2 billion by 2035, growing at a CAGR of 9.5% from 2026–2035.

The allergy immunotherapy market is witnessing robust and sustained growth, driven by the escalating global burden of allergic diseases - including allergic rhinitis, allergic asthma, atopic dermatitis, and food allergies - that collectively affect an estimated 30 to 40% of the world's population. Unlike symptomatic pharmacotherapies that provide temporary relief, allergy immunotherapy (AIT) addresses the underlying immunological mechanisms of allergic disease, offering patients the prospect of long-term desensitization and disease modification. The market is being reshaped by the rapid expansion of sublingual immunotherapy (SLIT) - in both tablet and drop formulations - that enables patient self-administration at home, dramatically improving treatment adherence and broadening the addressable patient population beyond traditional clinic-based subcutaneous injection regimens. Climate change prolonging pollen seasons, increasing urbanization intensifying allergen exposure, and growing physician and patient recognition of immunotherapy's disease-modifying benefits are collectively accelerating market adoption across all major geographies.

According to the World Allergy Organization, up to 40% of the global population now has at least one allergic disorder, and allergic rhinitis alone affects an estimated 500 million individuals worldwide - establishing allergy immunotherapy as one of the most scalable disease-modifying therapeutic opportunities in modern medicine, with immunotherapy now recognized by leading clinical guidelines as a preventative treatment that can change the course of allergic disease, reduce the risk of asthma progression, and deliver sustained remission that persists long after treatment completion.

Allergy Immunotherapy Market Size and Forecast

• Market Size in 2025: USD 2.1 Billion

• Market Size by 2035: USD 5.2 Billion

• CAGR: 9.5% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

To Get More Information On Allergy Immunotherapy Market - Request Free Sample Report

Allergy Immunotherapy Market Trends

• The rapid rise in SLIT tablet adoption fueled by the convenience of at-home use, better patient adherence rates, and wider regulatory approval for products containing allergens for grass pollen, ragweed, and house dust mites.

• The growing emphasis on the use of personalized protocols in allergy immunotherapy treatment through precision diagnostics such as component-resolved diagnostics and molecular allergen analysis.

• The rising prevalence of biologics in adjunct therapy treatment plans involving the addition of anti-IgE biologics like omalizumab to allergy immunotherapy regimens.

• The emergence of allergy immunotherapy programs for pediatric patients backed by clinical findings showing the benefit of early intervention in changing allergic disease progressions and preventing asthma and multiple sensitizations among children diagnosed with allergic rhinitis.

• The increasing use of digital adherence management software and remote patient engagement solutions in telemedicine platforms to help monitor patients and provide virtual consultation and treatment planning services for sublingual immunotherapy patients.

• The influence of climate change in prolonging pollination periods, widening geographically diverse allergens zones, and amplifying air allergens concentration levels, leading to increased occurrences of allergic diseases in general.

• The growing number of regulatory initiatives and pipeline developments in Asia Pacific and Latin America to expand immunotherapy market coverage in these regions besides North America and Europe.

The U.S. Allergy Immunotherapy Market was valued at USD 0.65 billion in 2025 and is expected to reach USD 1.55 billion by 2035, registering a CAGR of 9.1% during 2026–2035.

United States has a dominant leadership position in the worldwide Allergy Immunotherapy Market, supported by the widespread prevalence of allergies among around 31.8% of the U.S. population, as stated by the CDC, a sound clinical network comprising board-certified allergists and immunologists, and a favorable coverage reimbursement system for both subcutaneous and FDA-approved tablet formulations of sublingual immunotherapy. The US market gains strength through the dominance of major global AIT drug companies like ALK-Abelló, Stallergenes Greer, and Allergy Therapeutics, in addition to the ongoing pipeline activities conducted by biopharma companies such as Regeneron and Sanofi. The recent FDA approval in February 2024 of Xolair (omalizumab) for treating children and adult patients suffering from IgE-mediated food allergy is considered a significant regulatory breakthrough which has opened a new boundary in allergy immunotherapy in the U.S. market.

The U.S. market for allergy immunotherapy is undergoing a structural evolution - transitioning from a predominantly SCIT-driven, clinic-centric model toward a hybrid care paradigm that increasingly incorporates FDA-approved SLIT tablets for home administration, digital adherence monitoring platforms, and biologic combination protocols - delivering higher patient convenience, improved adherence metrics, and expanded access to disease-modifying allergy treatment for the estimated 50 million Americans who suffer from allergic diseases annually.

Allergy Immunotherapy Market Segment Insights

• Based on Type, Tablets accounted for the largest SLIT type share (~55%) in 2025; Drops expected to grow significantly as accessibility expands in emerging markets.

• Based on Treatment Type, Subcutaneous Immunotherapy (SCIT) accounted for the largest market share (~65%) in 2025; Sublingual Immunotherapy (SLIT) expected to be the fastest-growing segment (CAGR ~9.6%).

• Based on Allergy Type, Allergic Rhinitis accounted for the largest market share (~72%) in 2025; Food Allergy expected to be the fastest-growing allergy type segment (CAGR).

• Based on Distribution Channel, Hospital Pharmacy accounted for the largest market share in 2025; Online Pharmacy expected to be the fastest-growing distribution channel (CAGR).

Allergy Immunotherapy Market Segment Analysis

By Type, Tablets dominate within SLIT, Drops broadening emerging market access

In the sublingual immunotherapy category, tablets were estimated to contribute approximately 55% of SLIT type revenues in 2025, supported by the regulatory approvals gained by standardized allergen tablets targeting grass pollen, ragweed, and house dust mites via the U.S. FDA and European EMA pathways. Standardized allergen tablets ensure dosage accuracy, well-defined shelf life, and simpler prescription protocols for facilitating easy adoption. Prominent tablet formulations such as GRAZAX & ACARIZAX by ALK, and Odactra by Stallergenes Greer are some of the major products that have gained significant traction among allergists and general practitioners across North America and Europe.

On the other hand, sublingual drops (SLIT-liquid) are expected to lead in the SLIT type category in APAC, Latin America, and certain European geographies, where standardization processes for tablets are not mature. SLIT drops provide greater flexibilities in allergen formulations and cost advantages over standardized allergen tablets, which makes them suitable for customized multi-allergen immunotherapy products that can cater to markets with immature SLIT tablet regulations. Going forward, it is anticipated that sublingual drops will become increasingly important in enabling the access of allergy immunotherapy for patients through regulatory harmonization in emerging markets.

By Treatment Type, SCIT dominates, SLIT expected to grow fastest

Allergy shots (Subcutaneous immunotherapy; SCIT) comprised around 65% of the total Global Allergy Immunotherapy Market in 2025, thereby making it the leading mode of treatment. This superiority of subcutaneous immunotherapy (SCIT) is backed by decades of sound scientific research that has shown its effectiveness in alleviating symptoms and preventing disease progression, especially for patients with severe multiple allergies where sublingual immunotherapy (SLIT) is not available. Subcutaneous immunotherapy is delivered in controlled healthcare environments with medical professionals on-hand, ensuring correct doses and immediate response to any hypersensitivity reactions. It also has solid financial support systems in place in North America and Europe, strengthening its dominance in the market.

The sublingual immunotherapy (SLIT) market is expected to generate the highest CAGR of about 9.6% during 2026-2035 owing to its attractive patient benefits such as easy administration from the comfort of one’s home, higher compliance than injectable treatment regimens in clinic settings, and increased regulatory approval of SLIT tablets that target common allergens such as grass pollen, ragweed, and house dust mites. Due to its non-invasive characteristics, SLIT is more acceptable among pediatric and geriatric patients for whom injectable therapy would present a problem. Physicians' growing acceptance of data supporting SLIT’s efficacy and the involvement of large drugmakers in the SLIT tablet segment are driving the adoption of SLIT.

By Allergy Type, Allergic Rhinitis dominates, Food Allergy expected to grow fastest

Segment-wise, allergic rhinitis was the largest in terms of market share with 72% of the overall Allergy Immunotherapy Market revenue share recorded in 2025. A very high prevalence of allergic rhinitis cases worldwide, expectedly at a population level of 500 million individuals according to the World Allergy Organization, along with the highly reliable and scientifically established AIT protocols for treating pollen, house dust mite, and pet dander allergies, is responsible for leading the segment share. Regulatory approvals for allergic rhinitis immunotherapy are also the most advanced, with multiple SCIT and SLIT therapies available on the market. Research on the preventive effects of AIT on allergic rhinitis against asthma progression is adding to physician acceptance and increasing the duration of therapy.

The food allergy immunotherapy is forecasted to witness the maximum CAGR during the forecast period from 2026 to 2035. In February 2024, the U.S. Food and Drug Administration approved Xolair (omalizumab) for decreasing allergic reactions caused by exposure to various food allergens in children and adults, which was an unprecedented achievement in the regulation of food allergy immunotherapy market. Several pipeline OIT treatments of peanut allergy such as Palforzia (AR101) and promising clinical trials for food allergies like milk, egg, and tree nut have been identified as the prominent drivers of revenue growth of the segment under discussion. The high prevalence of food allergy cases in the U.S. (33 million) is considered a critical demand driver.

By Distribution Channel, Hospital Pharmacy dominates, Online Pharmacy expected to grow fastest

The hospital pharmacies captured the leading market share within the distribution channels in 2025 due to the need for professional supervision during the administration of subcutaneous immunotherapy, which requires the presence of a doctor while administering the medicine to avoid possible anaphylaxis reactions and proper handling of the allergen extracts in a controlled environment. They are the main distribution channels of SCIT medicines due to their close involvement in the whole process of treating patients across North America, Europe, and established Asia-Pacific countries. Their integration with allergist referral networks and insurance reimbursement processes strengthens their distribution channels' dominance.

The fastest-growing distribution channel from 2026 to 2035 will be the online pharmacy due to the rise in home administration SLIT tablets and drops prescribed, which do not need any clinical supervision when renewing prescriptions. They increase patient adherence to the drug regimen by providing them subscription-based refill options, automated refill reminders, and telemedicine prescription renewal options. Increasing use of e-prescription platforms and insurance company home delivery initiatives for SLIT products fuels their growth as a distribution channel worldwide.

Allergy Immunotherapy Market Regional Analysis:

North America Allergy Immunotherapy Market Insights

In terms of regional market share, North America occupied the market leader’s position with about 38% of the worldwide market. In this region, the leading economy that makes the most substantial contribution to the market’s growth is the US. The presence of a high prevalence rate of allergic diseases among the population, with more than 100 million people affected by such diseases; well-established clinical practices of allergists and immunologists, solid FDA regulatory policies concerning the approval of SCIT and SLIT tablets, and a well-functioning insurance reimbursement system for allergy immunotherapy treatment all contributed to making the country the most significant player in the field. Canada makes its own considerable contribution with the rising use of SLIT therapy, owing to seasonal allergic rhinitis rates and national health awareness initiatives related to allergies.

Get Customized Report as Per Your Business Requirement - Enquiry Now

Asia Pacific Allergy Immunotherapy Market Insights

The Asia Pacific region is projected to have the highest regional CAGR between 2026 and 2035, with an estimated annual growth rate of around 9.96%, representing the highest regional growth rate in the global market. The major contributors to regional market growth include China and India, fueled by the rising prevalence of allergic diseases due to factors such as urbanization, air pollution, industrialization, and climate change, which increase exposure to allergens. Increased investments in healthcare facilities, growing numbers of allergists, increased health insurance coverage, and awareness regarding the benefits of long-term immunotherapy among patients are contributing to rapid uptake of AIT.

Europe Allergy Immunotherapy Market Insights

Europe retained its dominance in the global Allergy Immunotherapy Market in 2025 as the second largest regional market in terms of size. Germany, France, and the United Kingdom are the leading contributors to the market. This can be attributed to standard AIT clinical protocols, reimbursement policies for SCIT and SLIT therapies, and initiatives by the governments to provide care for allergic diseases. Europe leads globally in terms of regulating SLIT, with approved SLIT products by ALK-Abelló, Stallergenes Greer, and Allergy Therapeutics. The changing climate in Central and Northern Europe increases the duration of pollen seasons, adding to the number of patients suffering from allergic rhinitis.

Middle East & Africa and Latin America Allergy Immunotherapy Market Insights

The MEA and Latin America markets offer promising avenues for the development of allergy immunotherapy due to an increase in the prevalence of allergies, urbanization, and healthcare modernization. Urban areas in UAE, Saudi Arabia, and South Africa have embraced the concept of immunotherapy due to increased investment by healthcare providers towards developing facilities specializing in allergy treatment. The UAE takes the lead among MEA countries in terms of revenue generation in the region, accounting for about 29% of total revenues. This is due to the highly developed healthcare industry in the country and a high number of high-income consumers with the ability to afford quality allergy treatments. Brazil is the key market player in Latin America, accounting for about 47% of total revenues.

Allergy Immunotherapy Market Growth Drivers:

• Favorable regulatory approvals and expanding product pipelines accelerating global AIT market access

The main structural factor supporting the growth of the Allergy Immunotherapy Market is the development of a growing number of approvals for SCIT and SLIT immunotherapies along with groundbreaking approvals of new types of treatments such as food allergy OIT and anti-IgE biologics combinations. Examples include recent FDA approval of omalizumab (Xolair) for treating multi-food allergies in February 2024, ALK's ACARIZAX and GRAZAX tablet approvals and Aimmune's Palforzia for peanut allergy OIT. These milestones are indicative of the revolutionary progress being achieved in the field of allergy immunotherapies, where each new approval adds to both the pool of patients that can benefit from treatment and creates new revenue opportunities, further cementing immunotherapy's status as a gold standard of allergy treatment.

The convergence of growing allergic disease burden, landmark regulatory approvals for next-generation immunotherapy products, and the structural shift toward patient-friendly sublingual and home-administration therapy formats is creating a sustained, multi-decade growth opportunity for allergy immunotherapy manufacturers - with the market's disease-modifying positioning commanding premium pricing and generating long-term treatment duration revenues that distinguish AIT from short-course symptomatic pharmaceutical alternatives across all major global markets.

Allergy Immunotherapy Market Restraints

• Long treatment duration, reimbursement gaps, and limited allergist access constraining patient adoption in underserved markets

A significant restraint in the Allergy Immunotherapy Market is the inherently long treatment duration of conventional immunotherapy protocols - typically 3 to 5 years for complete desensitization - which creates patient adherence challenges and can limit treatment initiation, particularly in markets where healthcare costs are borne directly by patients. Reimbursement gaps for allergy immunotherapy in developing economies and inconsistent insurance coverage across product formats and allergen types in even developed markets create access barriers for cost-sensitive patient populations. Additionally, the scarcity of board-certified allergists and immunology specialists in underserved regions - including rural areas of developed countries and across many emerging markets - limits the clinical capacity for SCIT administration and personalized immunotherapy protocol development, constraining market penetration beyond urban healthcare centers.

Allergy Immunotherapy Market Opportunities

• Personalized immunotherapy, food allergy biologics, and Asia Pacific market expansion

The emergence of personalized immunotherapy for allergies utilizing diagnostic methods based on molecular profiling and biomarkers of efficacy will be the biggest opportunity in terms of growth that exists in this market by providing personalized AIT treatments that increase efficacy while reducing the occurrence of adverse reactions. At the same time, the rapidly growing area of food allergy immunotherapy through oral immunotherapy, patch immunotherapy, and biologics acting as anti-IgE treatments for allergic reactions presents a strong opportunity given the previously neglected patient population and premium prices that can be charged for treatments to this group. The expansion into the Asia Pacific market provides significant structural opportunities for growth with increasing healthcare infrastructure, greater insurance coverage rates, and increasing medical awareness of AIT's value in China, India, Japan, and South Korea.

Recent Developments:

• 2026: ALK-Abelló extended its Allergy+ strategy, introducing the company’s latest generation of SLIT tablets for house dust mite and multiple allergens, aimed at the Asia Pacific and Latin America regions, along with a digital patient adherence application meant to boost SLIT therapy compliance in at-home administration.

• 2024 (June): The Board of Directors of ALK-Abelló announced their approval of a new strategy for ALK-Abelló, Allergy+, along with growth targets until 2028, centered on building upon ALK-Abelló’s leading position in SLIT and further developing its digital health initiatives while expanding into new geographies.

• 2024 (February): The FDA granted approval for Xolair (omalizumab), jointly developed by Novartis and Roche, for preventing allergic reactions following exposure to any single or multiple foods among adults and children above one year old with IgE-mediated food allergy, signifying a breakthrough application of monoclonal antibodies in protecting against multi-food allergies.

• 2024 (January): Finnish biopharmaceutical firm, Desentum, raised EUR 12 million in financing led by Springvest Oyj for the development of a new birch pollen allergy vaccine in clinical trials and a peanut allergy vaccine in preclinical studies, reflecting a major achievement in the pipeline development of innovative allergen immunotherapy drugs.

• 2025: Regeneron Pharmaceuticals and Sanofi extended their partnership on dupilumab (Dupixent) for the treatment of other atopic diseases, as the use of dupilumab as an add-on therapy to allergen immunotherapy regimens was found to be effective for hypersensitive patients with severe atopic dermatitis and allergic asthma disorders.

Allergy Immunotherapy Market Key Players

• ALK-Abelló A/S

• Stallergenes Greer plc

• Allergy Therapeutics plc

• HAL Allergy B.V.

• Merck KGaA

• DBV Technologies

• Aimmune Therapeutics (Nestlé Health Science)

• Regeneron Pharmaceuticals, Inc.

• Sanofi S.A.

• Novartis AG / Genentech (Roche)

• Biomay AG

• Torii Pharmaceutical Co., Ltd.

• Zydus Lifesciences Ltd.

• Cipla Ltd.

• LETI Pharma

• Bencard Allergie GmbH

• Alk-Scherax Arzneimittel GmbH

• Circassia Group plc

• Mylan N.V. (Viatris)

• Adamis Pharmaceuticals Corporation

Allergy Immunotherapy Market Report Scope: